Mexican Senate Votes to Cut Research Funding, Disaster Relief

Government leaders claim the reductions are necessary to free up assets to deal with COVID-19 and address corruption in research.

Written byLisa Winter
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM,
AGCUESTA

The Mexican Senate voted on Wednesday (October 21) to pass a bill that cuts funding from 109 public trust funds, which the government pays into. These accounts provide consistent funding, unrelated to the national budget. About one-third of the $68 billion pesos ($2.5 billion US) from the government that would ordinarily go into these trusts each year supports scientific research, and the rest is for sports, health initiatives, protections for journalists, and disaster relief.

As the Associated Press reports, Mexican President Andrés Manuel López Obrador called for the cuts back in April, citing widespread corruption and doubt that the funds actually reach and benefit Mexican citizens. López Obrador has also said that the money is needed to support the country’s response to the COVID-19 pandemic and that his administration inherited a lot of debt when he took office in 2018. According to The Guardian, $3 billion ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Lisa joined The Scientist in 2017. As social media editor, some of her duties include creating content, managing interactions, and developing strategies for the brand’s social media presence. She also contributes to the News & Opinion section of the website. Lisa holds a degree in Biological Sciences with a concentration in genetics, cell, and developmental biology from Arizona State University and has worked in science communication since 2012.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies